德国巴伐利亚州儿童胰岛自身抗体公共卫生筛查的产出
该研究在德国巴伐利亚州2015至2019年间对1.75至5.99岁儿童在初级保健儿科医生处进行健康婴儿访视时提供胰岛自身抗体筛查。共筛查90632名儿童,280名(0.31%;95%CI 0.27-0.35)检出症状前1型糖尿病(≥2种胰岛自身抗体),其中196例(0.22%)为1期,17例(0.02%)为2期,26例(0.03%)为3期,41例未分期。中位随访2.4年后,280例症状前1型糖尿病患儿3年进展至3期1型糖尿病的累积风险为24.9%(95%CI 18.5%-30.7%;54例;年化率9.0%)。2例发生糖尿病酮症酸中毒。症状前1型糖尿病患儿母亲在代谢分期时心理压力评分中位数(3[1-7])显著高于无胰岛自身抗体儿童母亲(2[1-4])(P=0.002),但随访12个月后下降(2[0-4])(P<0.001)。
要点
- 在德国巴伐利亚州1.75至5.99岁儿童中,初级保健机构为基础的胰岛自身抗体筛查检出症状前1型糖尿病(≥2种胰岛自身抗体)的患病率为0.31%(95%CI 0.27-0.35)。
- 280例症状前1型糖尿病患儿中,196例(0.22%)为1期(血糖正常),17例(0.02%)为2期(血糖异常),26例(0.03%)为3期(临床),41例未分期。
- 中位随访2.4年后,症状前1型糖尿病患儿3年进展至3期1型糖尿病的累积风险为24.9%(95%CI 18.5%-30.7%;54例;年化率9.0%)。
- 筛查发现的症状前1型糖尿病患儿中仅2例发生糖尿病酮症酸中毒。
- 症状前1型糖尿病患儿母亲在代谢分期时心理压力评分中位数(3[1-7])显著高于无胰岛自身抗体儿童母亲(2[1-4])(P=0.002),12个月随访后下降至2[0-4](P<0.001)。
适用人群与场景
- 德国巴伐利亚州1.75至5.99岁儿童,在初级保健儿科医生处进行健康婴儿访视时接受筛查。
- 检出多种胰岛自身抗体(症状前1型糖尿病)的儿童家庭被邀请参加糖尿病教育、代谢分期、心理压力评估和前瞻性随访直至临床糖尿病。
诊断标准与关键阈值
- 症状前1型糖尿病定义为2种或以上胰岛自身抗体阳性,并分为1期(血糖正常)、2期(血糖异常)或3期(临床)1型糖尿病。
研究设计与关键结果
- 研究类型为公共卫生筛查项目,筛查90632名儿童(中位年龄3.1岁[IQR 2.1-4.2],48.5%为女孩),280名(0.31%;95%CI 0.27-0.35)检出症状前1型糖尿病。
- 280例中196例(0.22%)为1期,17例(0.02%)为2期,26例(0.03%)为3期,41例未分期。
- 中位随访2.4年(IQR 1.0-3.2)后,另36名儿童进展至3期1型糖尿病;280例症状前1型糖尿病患儿3年累积风险为24.9%(95%CI 18.5%-30.7%;54例;年化率9.0%)。
- 2例发生糖尿病酮症酸中毒。
- 症状前1型糖尿病患儿母亲代谢分期时心理压力评分中位数3[1-7],无胰岛自身抗体儿童母亲为2[1-4](P=0.002);随访12个月后降至2[0-4](P<0.001)。
证据类型、等级与局限
- 证据类型:公共卫生筛查项目。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,这些发现可能为考虑对儿童进行基于人群的胰岛自身抗体筛查提供信息。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Public health screening for type 1 diabetes in its presymptomatic stages may reduce disease severity and burden on a population level.
OBJECTIVE: To determine the prevalence of presymptomatic type 1 diabetes in children participating in a public health screening program for islet autoantibodies and the risk for progression to clinical diabetes.
DESIGN, SETTING, AND PARTICIPANTS: Screening for islet autoantibodies was offered to children aged 1.75 to 5.99 years in Bavaria, Germany, between 2015 and 2019 by primary care pediatricians during well-baby visits. Families of children with multiple islet autoantibodies (presymptomatic type 1 diabetes) were invited to participate in a program of diabetes education, metabolic staging, assessment of psychological stress associated with diagnosis, and prospective follow-up for progression to clinical diabetes until July 31, 2019.
EXPOSURES: Measurement of islet autoantibodies.
MAIN OUTCOMES AND MEASURES: The primary outcome was presymptomatic type 1 diabetes, defined by 2 or more islet autoantibodies, with categorization into stages 1 (normoglycemia), 2 (dysglycemia), or 3 (clinical) type 1 diabetes. Secondary outcomes were the frequency of diabetic ketoacidosis and parental psychological stress, assessed by the Patient Health Questionnaire-9 (range, 0-27; higher scores indicate worse depression; ≤4 indicates no to minimal depression; >20 indicates severe depression).
RESULTS: Of 90 632 children screened (median [interquartile range {IQR}] age, 3.1 [2.1-4.2] years; 48.5% girls), 280 (0.31%; 95% CI, 0.27-0.35) had presymptomatic type 1 diabetes, including 196 (0.22%) with stage 1, 17 (0.02%) with stage 2, 26 (0.03%) with stage 3, and 41 who were not staged. After a median (IQR) follow-up of 2.4 (1.0-3.2) years, another 36 children developed stage 3 type 1 diabetes. The 3-year cumulative risk for stage 3 type 1 diabetes in the 280 children with presymptomatic type 1 diabetes was 24.9% ([95% CI, 18.5%-30.7%]; 54 cases; annualized rate, 9.0%). Two children had diabetic ketoacidosis. Median (IQR) psychological stress scores were significantly increased at the time of metabolic staging in mothers of children with presymptomatic type 1 diabetes (3 [1-7]) compared with mothers of children without islet autoantibodies (2 [1-4]) (P = .002), but declined after 12 months of follow-up (2 [0-4]) (P < .001).
CONCLUSIONS AND RELEVANCE: Among children aged 2 to 5 years in Bavaria, Germany, a program of primary care-based screening showed an islet autoantibody prevalence of 0.31%. These findings may inform considerations of population-based screening of children for islet autoantibodies.
参考来源
- Ziegler AG, Kick K, Bonifacio E, et al. Yield of a Public Health Screening of Children for Islet Autoantibodies in Bavaria, Germany. JAMA. 2020. PMID: 31990315. doi:10.1001/jama.2019.21565
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。